Major histocompatibility complex class I presenting Epstein-Barr virus latent membrane protein 1 and 2 peptides (MHC-I/EBV LMP1/2)

The Major Histocompatibility Complex (MHC) class I presenting Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) and 2 (LMP2) peptides is a specialized immunological target found on the surface of EBV-associated malignant cells (PMID: 33613511). EBV is an oncogenic herpesvirus associated with various cancers, including nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorders (PTLD). In these tumors, the virus expresses latent proteins such as LMP1 and LMP2, which are essential for viral persistence and oncogenesis. These proteins are proteolytically processed into short peptides and loaded onto MHC class I molecules for presentation to the immune system. This peptide-MHC (pMHC) complex is the primary recognition site for CD8+ cytotoxic T-lymphocytes, which can trigger apoptosis in the target cell upon binding via their T-cell receptors (TCRs). Therapeutic interventions, such as EBV-specific T-cell therapies (e.g., tabelecleucel) and TCR-engineered T-cells, leverage this mechanism to achieve highly specific anti-tumor activity (PMID: 31435456). The clinical utility of this target is highly dependent on the patient's HLA genotype, as specific peptides are only presented by certain HLA alleles like HLA-A*02:01 or HLA-A*11:01. Selective targeting of these complexes allows for the elimination of EBV-positive tumor cells while minimizing damage to healthy EBV-negative tissues.

Other names

HLA-EBV LMP1/2 complexEBV-specific peptide-MHC complexLMP1/2-HLA class I complexEpstein-Barr virus latent membrane protein antigen-MHC complex

Binding of T-cell receptors (TCRs) or TCR-like antibodies to the specific peptide-MHC complex, leading to the activation of cytotoxic T-lymphocytes and subsequent lysis of the EBV-positive tumor cells.